Santhera Pharmaceuticals Ag logo

Santhera Pharmaceuticals Ag(OTC) SPHDF

Market Cap$280.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-93%
5 Year+16%
1 Year+37%
1 Month-21%
$18.30
+0.00%
+0.00Today
Santhera Pharmaceuticals Ag last closing stock price
MetricPriceDate
Last closeUSD 18.302026-10-01
Santhera Pharmaceuticals Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.53%USD 19.792026-09-22
1 month-21.29%USD 23.252026-06-23
3 month-21.29%USD 23.252026-06-23
Year to date+37.08%USD 13.352025-12-16
1 year+37.39%USD 13.322025-09-29
3 year+77.81%USD 10.292023-09-28
5 year+15.82%USD 15.802021-09-27
Since inception-93.16%USD 267.502009-05-19

Santhera Pharmaceuticals Ag Financials at a Glance

Market Cap

$280.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 150.11M

Net Income (TTM)

-CHF 97.29M

EPS (TTM)

-$2.88

P/E Ratio

-6.35

Dividend

$0.00

Beta (Volatility)

-0.05 (Low)

Price

$18.30

Volume

61

Open

$18.30

Previous Close

$18.30

Daily Range

$18.30 - $18.30

52-Week Range

$12.28 - $23.25

Estimated Earnings Date

Apr 29, 2027

SPHDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Santhera Pharmaceuticals Ag

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on developing and selling medicines for rare neuromuscular and pulmonary diseases. The company operates in Europe, North America, and Asia, addressing high unmet medical needs with innovative therapies.

Products and Services
  • Vamorolone for Duchenne muscular dystrophy treatment
  • Lonodelestat for cystic fibrosis and neutrophilic pulmonary diseases
  • Pipeline targeting rare diseases with significant market potential
Growth Outlook
  • Recent revenue of CHF 47.9 million indicates strong market interest
  • Pipeline candidates address critical unmet needs in rare diseases
  • Strategic focus on expanding market presence in key regions
Financial Highlights
  • Trailing twelve months (TTM) revenue of CHF 143.5 million
  • Recent quarterly net income loss of CHF 21.3 million
  • Current ratio of 1.73 suggests strong short-term financial health
Santhera Pharmaceuticals Holding AG is positioned in the biotechnology sector, focusing on innovative treatments for rare diseases. The company's lead product, Vamorolone, is in development for Duchenne muscular dystrophy, a condition with significant unmet medical needs. Additionally, Lonodelestat targets cystic fibrosis, further diversifying the company's portfolio. The recent revenue figures reflect a growing interest in the company's offerings, while the strategic focus on expanding its market presence in Europe, North America, and Asia highlights its commitment to addressing critical healthcare challenges. Despite recent net income losses, the company's current ratio indicates a solid short-term financial position, allowing for continued investment in research and development. Overall, Santhera Pharmaceuticals presents a compelling opportunity for investors interested in the biotechnology sector, particularly in companies dedicated to addressing rare diseases with high unmet medical needs.
AI Generated • Oct 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

93.6

CEO

Dario Eklund

Website

www.santhera.com

Headquarters

Pratteln, BL 4133, CH

SPHDF Financials

Key Financial Metrics (TTM)

Gross Margin

40.26%

Operating Margin

-8.93%

Net Income Margin

-31.46%

Return on Equity

354.99%

Return on Capital

-44.00%

Return on Assets

-21.69%

Earnings Yield

-15.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$280.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.30M

Volume

61

Avg. Volume

42.631

Financials (TTM)

Gross Profit

CHF 46.95M

Operating Income

-CHF 60.04M

EBITDA

-CHF 37.33M

Operating Cash Flow

-CHF 40.32M

Capital Expenditure

-CHF 239.69K

Free Cash Flow

-CHF 40.56M

Cash & ST Invst.

CHF 41.53M

Total Debt

CHF 41.04M

Santhera Pharmaceuticals Ag Performance Analysis

Santhera Pharmaceuticals Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 7,824,597N/A
20232023-12-31CHF 115,076,8361370.7%
20242024-12-31CHF 44,417,441-61.4%
20252025-12-31CHF 92,939,529109.2%
Santhera Pharmaceuticals Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3177.2%
Q22025-06-30-4.0%
Q42025-12-31121.5%
Q22026-06-30-10.0%
Santhera Pharmaceuticals Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -12.21-31.3%
20232023-12-31CHF 5.58N/A
20242024-12-31CHF -4.19N/A
20252025-12-31CHF -4.568.8%
Santhera Pharmaceuticals Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-73.3%
Q22025-06-30-29.9%
Q42025-12-3174.3%
Q22026-06-30-91.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CHF 47.90M

+239.4%

Gross Profit

CHF 17.79M

+99.9%

Gross Margin

37.13%

N/A

Market Cap

$280.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.59M

N/A

Employees

78

N/A

Net Income

-CHF 21.33M

-39.8%

EBITDA

-CHF 3.80M

+74.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CHF 41.53M

+151.9%

Total Debt

CHF 41.04M

+55.6%

Accounts Receivable

CHF 11.42M

+9.4%

Inventory

CHF 24.50M

+306.7%

Long Term Debt

CHF 30.08M

+791.0%

Short Term Debt

CHF 10.96M

-54.2%

Return on Assets

-21.69%

N/A

Return on Invested Capital

-9.17%

N/A

Free Cash Flow

CHF 14.66M

+195.4%

Operating Cash Flow

CHF 14.69M

+196.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLLCFMolecular Partners AG
$4.01+0.00%
IPHYFInnate Pharma S.A.
$1.51+0.00%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
NDTPNDT Pharmaceuticals Inc.
$0.35-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About SPHDF

What is the current price of Santhera Pharmaceuticals Ag?

Santhera Pharmaceuticals Ag is trading at $18.30 per share.

What is the 52-week range for Santhera Pharmaceuticals Ag?

Over the past 52 weeks, Santhera Pharmaceuticals Ag has traded between $12.28 and $23.25.

How much debt does Santhera Pharmaceuticals Ag have?

As of the most recent reporting period, Santhera Pharmaceuticals Ag reported total debt of CHF 123.40M.

How much cash does Santhera Pharmaceuticals Ag have on hand?

Santhera Pharmaceuticals Ag reported CHF 28.32M in cash and cash equivalents in its most recent financial results.

What is Santhera Pharmaceuticals Ag’s dividend yield?

Santhera Pharmaceuticals Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services